Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Systemic Sclerosis–Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration–Approved Therapies in Clinical Practice
Dinesh Khanna, Alain Lescoat, David Roofeh, et al.
Arthritis & Rheumatology (2021) Vol. 74, Iss. 1, pp. 13-27
Open Access | Times Cited: 104

Showing 1-25 of 104 citing articles:

Interleukin-6 cytokine: An overview of the immune regulation, immune dysregulation, and therapeutic approach
Mansur Aliyu, Fatema Tuz Zohora, Abubakar Umar Anka, et al.
International Immunopharmacology (2022) Vol. 111, pp. 109130-109130
Open Access | Times Cited: 154
Expert consensus on the management of systemic sclerosis-associated interstitial lung disease
Franck Rahaghi, Vivien Hsu, Robert J. Kaner, et al.
Respiratory Research (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 97
Treatment of Systemic Sclerosis–associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline
Ganesh Raghu, Sydney B. Montesi, Richard M. Silver, et al.
American Journal of Respiratory and Critical Care Medicine (2023) Vol. 209, Iss. 2, pp. 137-152
Open Access | Times Cited: 67
Immune cell dysregulation as a mediator of fibrosis in systemic sclerosis
Dan Fang, Beidi Chen, Alain Lescoat, et al.
Nature Reviews Rheumatology (2022) Vol. 18, Iss. 12, pp. 683-693
Closed Access | Times Cited: 51
Perspective for Discovery of Small Molecule IL-6 Inhibitors through Study of Structure–Activity Relationships and Molecular Docking
Hossam Nada, Aneesh Sivaraman, Qili Lu, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 7, pp. 4417-4433
Closed Access | Times Cited: 25
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis
Robert Spiera, Masataka Kuwana, Dinesh Khanna, et al.
Arthritis & Rheumatology (2023) Vol. 75, Iss. 9, pp. 1608-1618
Open Access | Times Cited: 25
The 2024 British Society for Rheumatology guideline for management of systemic sclerosis
Christopher P. Denton, Enrico De Lorenzis, Elen Roblin, et al.
Lara D. Veeken (2024) Vol. 63, Iss. 11, pp. 2956-2975
Open Access | Times Cited: 14
Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON
Yannick Allanore, Madelon C Vonk, Oliver Distler, et al.
Annals of the Rheumatic Diseases (2022) Vol. 81, Iss. 12, pp. 1722-1729
Open Access | Times Cited: 31
Multidisciplinary teams in the clinical care of fibrotic interstitial lung disease: current perspectives
Vincent Cottin, Fernando J. Martinez, Vanessa Smith, et al.
European Respiratory Review (2022) Vol. 31, Iss. 165, pp. 220003-220003
Open Access | Times Cited: 31
Dysregulated B cell function and disease pathogenesis in systemic sclerosis
Claire F. Beesley, Nina Goldman, Taher E. Taher, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 21
Biomarkers in the Pathogenesis, Diagnosis, and Treatment of Systemic Sclerosis
Maheswari Muruganandam, Angie Ariza‐Hutchinson, Rosemina A Patel, et al.
Journal of Inflammation Research (2023) Vol. Volume 16, pp. 4633-4660
Open Access | Times Cited: 21
A 24‐Week , Phase IIa , Randomized, Double‐blind, Placebo‐controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis ( NOVESA )
Dinesh Khanna, Christopher P. Denton, Daniel E. Furst, et al.
Arthritis & Rheumatology (2023) Vol. 75, Iss. 8, pp. 1434-1444
Open Access | Times Cited: 18
Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study
Corrado Campochiaro, Giacomo De Luca, Maria Grazia Lazzaroni, et al.
RMD Open (2023) Vol. 9, Iss. 1, pp. e002850-e002850
Open Access | Times Cited: 18
Systemic sclerosis interstitial lung disease: unmet needs and potential solutions
Vasiliki Liakouli, Antonio Ciancio, Francesco Del Galdo, et al.
Nature Reviews Rheumatology (2023) Vol. 20, Iss. 1, pp. 21-32
Closed Access | Times Cited: 16
Management of Connective Tissue Disease–related Interstitial Lung Disease
Sakir Ahmed, Rohini Handa
Current Pulmonology Reports (2022) Vol. 11, Iss. 3, pp. 86-98
Open Access | Times Cited: 23
Beyond very early systemic sclerosis: deciphering pre‑scleroderma and its trajectories to open new avenues for preventive medicine
Alain Lescoat, Silvia Bellando-Randone, Corrado Campochiaro, et al.
The Lancet Rheumatology (2023) Vol. 5, Iss. 11, pp. e683-e694
Open Access | Times Cited: 14
Interstitial Lung Disease Associated with Systemic Sclerosis
Valentine Mismetti, Salim Si‐Mohamed, Vincent Cottin
Seminars in Respiratory and Critical Care Medicine (2024) Vol. 45, Iss. 03, pp. 342-364
Closed Access | Times Cited: 5
Results from the international collaborative systematic literature review informing the 2023 EULAR recommendations for the treatment of systemic sclerosis
Alain Lescoat, Eugenia Bertoldo, Jelena Čolić, et al.
Annals of the Rheumatic Diseases (2024) Vol. 84, Iss. 1, pp. 77-92
Open Access | Times Cited: 5
CAMAF: Context-Aware Multimodal Alignment Framework for explainable lung disease risk stratification
Subba Rao Dusari, Nagendra Panini Challa
Expert Systems with Applications (2025), pp. 127398-127398
Closed Access
Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies
Alain Lescoat, David Roofeh, Masataka Kuwana, et al.
Clinical Reviews in Allergy & Immunology (2021) Vol. 64, Iss. 3, pp. 239-261
Closed Access | Times Cited: 31
Mediators of systemic sclerosis-associated interstitial lung disease (SSc-ILD): systematic review and meta-analyses
Aislin Fields, Koray N Potel, Rhandel Cabuhal, et al.
Thorax (2022) Vol. 78, Iss. 8, pp. 799-807
Open Access | Times Cited: 21
Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma
Alain Lescoat, Suiyuan Huang, Patrícia Carreira, et al.
JAMA Dermatology (2023) Vol. 159, Iss. 8, pp. 837-837
Open Access | Times Cited: 12
Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival
Pia Moinzadeh, Francesco Bonella, Max Oberste, et al.
CHEST Journal (2023) Vol. 165, Iss. 1, pp. 132-145
Open Access | Times Cited: 12
Efficacy and Safety of Nintedanib in Patients with Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD): A Real-World Single Center Experience
Maria Boutel, Afroditi Boutou, Georgia Pitsiou, et al.
Diagnostics (2023) Vol. 13, Iss. 7, pp. 1221-1221
Open Access | Times Cited: 11
Interstitial Lung Disease
Cosimo Bruni, Corrado Campochiaro, Jeska K de Vries-Bouwstra
Rheumatic Disease Clinics of North America (2023) Vol. 49, Iss. 2, pp. 279-293
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top